Modafinil Eg

Modafinil, the active ingredient in Modafinil EG, is a eugeroic presented as a tablet for oral use. It treats excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder. It is approved in the European Union and classified under ATC code N06BA07.

GNH USA supplies Modafinil EG as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers. Our distribution network ensures timely delivery across multiple continents.

Modafinil acts on the central nervous system to promote wakefulness in disorders characterized by excessive daytime sleepiness.

- Narcolepsy: reduces daytime sleepiness and improves alertness in patients with this chronic sleep disorder. - Obstructive sleep apnea: alleviates residual sleepiness when used alongside standard respiratory therapy. - Shift work disorder: helps maintain alertness during scheduled work hours for individuals with irregular work schedules.

Modafinil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Nausea: occasional gastrointestinal discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Anxiety: feelings of nervousness or restlessness. - Dizziness: light‑headed sensation, especially on standing. - Dry mouth: reduced salivation leading to oral dryness.

Serious or Rare Side Effects: - Severe skin reactions: rash, Stevens‑Johnson syndrome, or toxic epidermal necrolysis. - Psychiatric events: hallucinations, mania, or worsening of depression. - Cardiovascular issues: hypertension, palpitations, or chest pain. - Allergic reactions: anaphylaxis, facial swelling, or breathing difficulty.

When prescribing Modafinil, clinicians should consider several precautionary measures to ensure patient safety.

- Cardiovascular assessment: evaluate blood pressure and heart disease history before initiation. - Psychiatric monitoring: watch for anxiety, depression, or psychotic symptoms during therapy. - Discontinuation: avoid abrupt cessation to reduce rebound sleepiness. - Hepatic function: adjust use in patients with liver impairment. - Allergy: discontinue immediately if hypersensitivity develops. - Store at ambient temperature: keep in the original pack, protect from moisture.

Modafinil can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase Modafinil plasma levels. - Oral contraceptives: reduced hormonal efficacy, increasing risk of unintended pregnancy. - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine): may modestly raise Modafinil concentrations. - CYP2C9 inhibitors (e.g., fluconazole): potential increase in exposure. - Antihypertensive agents: additive blood pressure‑lowering effect. - Alcohol: may enhance central nervous system depression.